To maximize the commercial potential of our technology, Intarcia continues to evaluate new opportunities for novel and proprietary product candidates, with efforts focused around two areas:
To learn more about Intarcia's partnering opportunities or accessing Intarcia's formulation and delivery technology platform, please contact Intarcia Business Development at busdev@intarcia.com.

Intarcia's lead product candidate, ITCA 650 is being developed for the treatment of Type 2 Diabetes and employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy.